Keyphrases
Antiretroviral Therapy
58%
AIDS/HIV
57%
Human Immunodeficiency Virus Type 1 (HIV-1)
57%
HIV Patients
42%
Mali
36%
Nigeria
27%
Lamivudine
26%
Zidovudine
26%
Stavudine
24%
Nevirapine
20%
COVID-19
20%
CD4 Count
19%
HIV Infection
17%
Antiretroviral
16%
Protease Inhibitors
16%
Bamako
15%
Trend Analysis
14%
Longitudinal Trends
14%
Efavirenz
14%
Nucleoside Reverse Transcriptase Inhibitors
14%
Human Immunodeficiency Virus Infection
13%
Resource-limited Settings
13%
Antiviral Activity
13%
Lopinavir
12%
Confidence Interval
12%
Atazanavir
11%
Cytomegalovirus Retinitis
11%
HIV Viral Load
11%
AIDS Clinical Trials
11%
Hepatitis B Virus
11%
Antiretroviral Naïve
11%
COVID-19 Pandemic
11%
Surveillance Metrics
11%
Pneumocystis Jirovecii
10%
Nigerians
10%
Virological Failure
10%
Highly Active Antiretroviral Therapy (HAART)
10%
Didanosine
10%
Ritonavir
9%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
9%
Mycobacterium Tuberculosis (M. tb)
9%
HIV RNA
9%
World Health Organization
9%
Clinical Trials
9%
Antiviral Drugs
9%
Viral Load
9%
Raltegravir
9%
Tuberculosis
9%
Darunavir
8%
MRNA Level
8%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Human Immunodeficiency Virus Infection
25%
Stavudine
23%
Zidovudine
22%
Infection
21%
Nevirapine
20%
Lamivudine
20%
Clinical Trial
20%
Proteinase Inhibitor
19%
RNA Directed DNA Polymerase Inhibitor
17%
Human Immunodeficiency Virus 1
15%
Pharmacokinetics
14%
Efavirenz
13%
SARS Coronavirus
12%
Drug Resistance
12%
Didanosine
10%
Nonnucleoside Reverse Transcriptase Inhibitor
9%
Antivirus Agent
8%
Antiviral Activity
8%
Diseases
8%
Lopinavir Plus Ritonavir
8%
Pandemic
7%
Placebo
7%
Adverse Event
7%
Tolerability
7%
Nucleoside
7%
Atazanavir Plus Ritonavir
6%
Human Immunodeficiency Virus 1 Infection
6%
Atazanavir
6%
Virus RNA
6%
Raltegravir
6%
Pneumocystis Pneumonia
6%
Hepatitis B Virus
6%
Prevalence
5%
Combination Therapy
5%
Ritonavir
5%
Amprenavir
5%
Uterine Cervix Cancer
5%
Indinavir
5%
Monotherapy
5%
Tenofovir
5%
Medicine and Dentistry
Human Immunodeficiency Virus
67%
Antiretroviral Therapy
26%
COVID-19
19%
Infection
18%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Clinical Trial
14%
Hepatitis B Virus
11%
Zidovudine
9%
Cytomegalovirus Retinitis
8%
Proteinase Inhibitor
8%
Drug Resistance
8%
Cervical Cancer
7%
Mixed Infection
7%
Human Immunodeficiency Virus 1
7%
Reverse-Transcriptase Inhibitor
7%
Cell Count
7%
Efavirenz
6%
Human Immunodeficiency Virus Infection
6%
Public Health
6%
Lamivudine
6%
Wart Virus
6%
Acquired Immune Deficiency Syndrome
6%
Mycobacterium Tuberculosis
6%
Cervical Cancer Screening
5%
Uterine Cervix Cytology
5%
Cohort Analysis
5%
Arm
5%
Atazanavir Plus Ritonavir
5%
Prevalence
5%
Odds Ratio
5%